Background {#section5-2040622320916026}
==========

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive disability, systemic complications, early death, and socioeconomic cost.^[@bibr1-2040622320916026]^ RA affects approximately 1% of the global population,^[@bibr2-2040622320916026]^ and most of those affected are women. RA is a multifactorial autoimmune disease affected by environmental and genetic factors. Presenting at any age, RA often leads to irreversible deformity.

Methotrexate (MTX) is a first-line disease-modifying antirheumatic drug (DMARD) for RA. Owing to its efficacy and low cost, both the American College of Rheumatology (ACR)^[@bibr3-2040622320916026]^ and the European League Against Rheumatism (EULAR)^[@bibr4-2040622320916026]^ currently recommend low-dose (5--25 mg/week) MTX monotherapy as the initial treatment for patients newly diagnosed with RA. Though MTX is indispensable in the treatment of RA, it is difficult for some patients to use due to adverse reactions or patient comorbidities.^[@bibr5-2040622320916026]^ About 30--45% of RA patients who receive MTX suffer from adverse events, and 16% of RA patients discontinue MTX due to adverse events.^[@bibr6-2040622320916026]^ MTX was reported to be associated with various adverse drug events such as hepatotoxicity, renal dysfunction, gastrointestinal dysfunction, pancytopenia, interstitial pneumonia, and increased susceptibility to infection.^[@bibr7-2040622320916026]^

MTX is an antagonist of the essential nutrient folic acid and has anti-inflammatory and antiproliferative effects. MTX inhibits the progression of RA, alleviates joint pain and damage, and delays loss of mobility.^[@bibr8-2040622320916026]^ Interindividual differences in susceptibility to adverse events are suggested to be due to genetic polymorphisms related to the capacity of transporters and enzymes that mediate the biotransformation and accumulation/elimination of MTX in the body.^[@bibr9-2040622320916026]^ Therefore, identifying predictors of MTX toxicity is important for the management of RA to achieve individualized treatment. Accumulating evidence suggests associations between gene polymorphisms and MTX toxicity in RA patients. A number of meta-analyses,^[@bibr10-2040622320916026][@bibr11-2040622320916026][@bibr12-2040622320916026][@bibr13-2040622320916026][@bibr14-2040622320916026][@bibr15-2040622320916026][@bibr16-2040622320916026][@bibr17-2040622320916026][@bibr18-2040622320916026][@bibr19-2040622320916026][@bibr20-2040622320916026]--[@bibr21-2040622320916026]^ focused mostly on 5,10-methylenetetrahydrofolate reductase (MTHFR) single nucle-otide polymorphisms (SNPs) have been conducted to determine whether gene polymorphisms can predict adverse events of MTX therapy in patients with RA. However, the results of these meta-analyses were inconsistent and inconclusive. In 2017, we published a systematic review and meta-analysis to evaluate the correlations between gene polymorphisms and MTX-related toxicity in RA patients under one genetic model. We found a significant association between the toxicity of MTX and the reduced folate carrier 1 (RFC-1) 80G\>A (rs1051266) polymorphism in RA patients.^[@bibr22-2040622320916026]^ Here, we performed an updated meta-analysis to assess the relationships between gene polymorphisms and MTX-related toxicity under various genetic models. In addition, we conducted a retrospective cohort study to further validate these evidence-based findings.

Materials and methods {#section6-2040622320916026}
=====================

Updated meta-analysis {#section7-2040622320916026}
---------------------

### Search strategy and study selection {#section8-2040622320916026}

Relevant studies investigating the association between gene polymorphisms and MTX adverse events in RA were collected from the PubMed database and the EMBASE database (OvidSP) until December 2017. The search strategy has been detailed in our previous article.^[@bibr22-2040622320916026]^ Details of the search flow are summarized in [Figure 1](#fig1-2040622320916026){ref-type="fig"}. Studies satisfying the following inclusion criteria were included in the meta-analysis: (1) articles investigating the associations between gene polymorphisms and toxicity in RA patients treated with MTX; (2) extractable genotype and allele frequencies to calculate odds ratios (ORs) and 95% confidence intervals (CIs); (3) full-text articles published in English. The major exclusion criteria were: (1) duplicate publications; (2) letter, comments, reviews, meta-analyses, editorials, or conference abstracts; (3) insufficient genotype or allele data for cases with and without adverse events; (4) non-English articles.

![Flow chart summarizing study identification and selection.\
DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; RA, rheumatoid arthritis.](10.1177_2040622320916026-fig1){#fig1-2040622320916026}

### Data extraction {#section9-2040622320916026}

References were screened, and all available data were extracted carefully from each study by two of the authors independently using a predetermined data collection template. Potential conflicts were resolved by a third investigator. The following data were included: name of first author, year of publication, country, ethnicity of study population, sample size, numbers of cases with and without adverse events, genotype frequencies of adverse events, study conclusions, toxicity criteria, and adverse events such as overall adverse events and hepatic, central nervous system (CNS), hematological, gastrointestinal, and respiratory adverse events.

### Statistical analysis {#section10-2040622320916026}

Gene SNPs detected in more than two studies were included in the meta-analysis. Genotype frequencies of the MTHFR 677C\>T (rs1801133), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) 347C\>G (rs2372536), RFC-1 80G\>A (rs1051266), adenosine triphosphate-binding cassette B1 (ABCB1) 3435C\>T (rs1045642), MTHFR 1298A\>C (rs1801131), MTR2756 A\>G (rs1805087), MTRR 66A\>G (rs1801394), g-folylpolyglutamate synthetase (FPGS) 1994A\>G (rs10106), AMPD1 34C\>T (rs17602729), ITPA 94C\>A (rs1127354), glutamyl hydrolase (GGH)-401C\>T (rs3758149), GGH 16T\>C (rs1800909), GGH 452C\>T (rs11545078), ABCC2 C\>T (rs4148396), ABCG2 914C\>A (rs2231142), FPGS 2572C\>T (rs1544105), thymidylate synthetase (TYMS) 28-bp tandem repeat (rs34743033), ADORA2A 4221164C\>T (rs2267076), ADORA2A 24429543C\>T (rs2298383), and MTHFD1 1958G\>A (rs2236225) polymorphisms were determined. Five comparison models were analyzed: the pre-allele model (A *versus* a), dominant model (AA *versus* Aa+aa), recessive model (aa *versus* AA+Aa), codominant model (Aa *versus* AA+aa), and homozygotic model (AA *versus* aa), where 'A' refers to the wild-type allele and 'a' refers to a mutated allele. Subgroup analysis according to ethnicity (European, African, and East Asian) was performed. The detailed method of statistical analysis has been described in our previous articles.^[@bibr22-2040622320916026],[@bibr23-2040622320916026]^

Retrospective cohort study {#section11-2040622320916026}
--------------------------

Patient recruitment and assessment have been described in detail elsewhere.^[@bibr24-2040622320916026],[@bibr25-2040622320916026]^ Briefly, RA patients who fulfilled the 1987 RA criteria of the American College of Rheumatology (ACR) were recruited from April 2016 to April 2018 at China--Japan Friendship Hospital and the People's Hospital of Yichun, China. This study was registered on the Chinese Clinical Trial Registry (ChiCTR-RNC-14004887). Informed consent was obtained from all individual participants included in the study, which was approved by the Ethics Committee of the People's Hospital of Yichun (ethics ID: 2014-01).

All patients were treated with MTX orally for at least 3 months. Patients were monitored for MTX-related toxicity by clinical assessment and laboratory investigations. Genomic DNA was isolated from 2 ml ethylenediaminetetraacetic acid (EDTA)-anticoagulated whole blood samples using commercial DNA extraction kits (Qiagen, Hilden, Germany). For each DNA sample, MTHFR 677C\>T (rs1801133), RFC-1 80G\>A (rs1051266), ATIC 347C\>G (rs2372536), and ABCB1 3435C\>T (rs1045642) polymorphisms were detected by PCR and product sequencing.

The Hardy-Weinberg equilibrium (HWE) of the patients was calculated by chi-square statistics. All statistical data are described as numbers and frequencies. The mean and standard deviation (±SD) are used to describe sample tests, while the median and interquartile range (± IQR) are used for non-Gaussian distributed variables. Allele and genotype association analyses with regard to MTX-related adverse events were performed using the χ^2^ test. Correlation of the associated SNP and the adverse events was performed by logistic regression analysis. Logistic regression models were built depending on age and gender to estimate adjusted ORs. Allele and genotype risk were assessed using OR and 95% confidence interval (CI) values. *P* \< 0.05 was regarded as statistically significant. Statistical analysis was carried out using SPSS 20.0 Version (IBM Corporation, Armonk, NY, USA).

Results {#section12-2040622320916026}
=======

Meta-analysis {#section13-2040622320916026}
-------------

We conducted an updated meta-analysis to evaluate the association between gene polymorphism and toxicity in MTX-treated RA patients. A total of 862 citations were collected from electronic databases, and, after excluding duplicates, screening titles and abstracts, and reading full articles, a total of 39 articles were included.^[@bibr8-2040622320916026],[@bibr9-2040622320916026],[@bibr26-2040622320916026][@bibr22-2040622320916026][@bibr23-2040622320916026][@bibr24-2040622320916026][@bibr25-2040622320916026][@bibr26-2040622320916026][@bibr27-2040622320916026][@bibr28-2040622320916026][@bibr29-2040622320916026][@bibr30-2040622320916026][@bibr31-2040622320916026][@bibr32-2040622320916026][@bibr33-2040622320916026][@bibr34-2040622320916026][@bibr35-2040622320916026][@bibr36-2040622320916026][@bibr37-2040622320916026][@bibr38-2040622320916026][@bibr39-2040622320916026][@bibr40-2040622320916026][@bibr41-2040622320916026][@bibr42-2040622320916026][@bibr43-2040622320916026][@bibr44-2040622320916026][@bibr45-2040622320916026][@bibr46-2040622320916026][@bibr47-2040622320916026][@bibr48-2040622320916026][@bibr49-2040622320916026][@bibr50-2040622320916026][@bibr51-2040622320916026][@bibr52-2040622320916026][@bibr53-2040622320916026][@bibr54-2040622320916026][@bibr55-2040622320916026][@bibr56-2040622320916026][@bibr57-2040622320916026][@bibr58-2040622320916026][@bibr59-2040622320916026][@bibr60-2040622320916026][@bibr61-2040622320916026]-[@bibr62-2040622320916026]^ The study selection process is presented in [Figure 1](#fig1-2040622320916026){ref-type="fig"}. The main characteristics of studies are summarized in Additional file 1: [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026).

Overall, 23 studies (including 1433 cases presenting adverse events and 2384 cases without adverse events) were included in the meta-analysis of the MTHFR 677C\>T (rs1801133) polymorphism. Regardless of ethnicity, the MTHFR 677C\>T (rs1801133) polymorphism was related to presenting adverse events in the recessive model (OR = 1.438, 95% CI: 1.144--1.806, *p* = 0.002). No significant evidence of a relationship between the MTHFR 677C\>T (rs1801133) polymorphism and MTX-related toxicity was observed in the pre-allele model, dominant model, codominant model, and homozygotic model (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). Moreover, significant between-study heterogeneity was observed in the pre-allele (I^2^ = 77.7, χ^2^ = 80.64, *p* \< 0.001), dominant (I² = 74.2, χ^2^ = 85.38, *p* \< 0.001), codominant (I^2^ = 50.2, χ^2^ = 36.18, *p* = 0.007), and homozygotic models (I^2^ = 59.7, χ^2^ = 42.21, *p* = 0.001), but not in the recessive model (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

In the East Asian population (549 presenting adverse events and 594 without adverse events), the MTHFR 677C\>T (rs1801133) polymorphism was associated with the presence of adverse events in the recessive model (OR = 1.698, 95% CI: 1.176--2.451, *p* = 0.005) ([Figure 2](#fig2-2040622320916026){ref-type="fig"}) but with the absence of adverse events in the dominant model (OR = 0.497, 95% CI: 0.248--0.998, *p* = 0.049) ([Figure 3](#fig3-2040622320916026){ref-type="fig"}). No significant evidence of a relationship between the MTHFR 677C\>T (rs1801133) polymorphism and MTX-related toxicity was observed in the pre-allele model, codominant model and homozygotic model (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). In addition, no significant association was observed in the European population in any of the five models. (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

![Forest plot showing the association between MTHFR 677C\>T (rs1801133) polymorphism and MTX-related toxicity (recessive model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig2){#fig2-2040622320916026}

![Forest plot showing the association between MTHFR 677C\>T (rs1801133) polymorphism and MTX-related toxicity (dominant model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig3){#fig3-2040622320916026}

Seven studies (444 presenting adverse events and 920 without adverse events) were included in the meta-analysis of the ATIC 347C\>G (rs2372536) polymorphism. Regardless of ethnicity, the ATIC 347C\>G (rs2372536) polymorphism was not related to the presence and/or absence of adverse events in all five genetic models (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). Moreover, significant between-study heterogeneity was not observed in any of the five models (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

By contrast, in the European population (161 presenting adverse events and 457 without adverse events), the ATIC 347C\>G (rs2372536) polymorphism was correlated with the absence of adverse events in the pre-allele model (OR = 0.756, 95% CI: 0.575--0.995, *p* = 0.046) ([Figure 4](#fig4-2040622320916026){ref-type="fig"}) and dominant model (OR = 0.679, 95% CI: 0.468--0.985, *p* = 0.041) ([Figure 5](#fig5-2040622320916026){ref-type="fig"}) but not in the recessive model, codominant model, or homozygotic model (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). No significant association was observed in the East Asian population (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

![Forest plot showing the association between ATIC 347C\>G (rs2372536) polymorphism and MTX-related toxicity (pre-allele model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig4){#fig4-2040622320916026}

![Forest plot showing the association between ATIC 347C\>G (rs2372536) polymorphism and MTX-related toxicity (dominant model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig5){#fig5-2040622320916026}

For the RFC-1 80G\>A (rs1051266) polymorphism, 12 studies (906 presenting adverse events and 1278 without adverse events) were included in the meta-analysis. The RFC-1 80G\>A (rs1051266) polymorphism was not related to the presence and/or absence of adverse events in the overall population (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). Moreover, significant between-study heterogeneity was not observed in all five models (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

However, in the European population (503 presenting adverse events and 865 without adverse events), the RFC-1 80G\>A (rs1051266) polymorphism was related to the presence of adverse events in the dominant model (OR = 1.352, 95% CI: 1.039--1.760, *p* = 0.025) ([Figure 6](#fig6-2040622320916026){ref-type="fig"}) but not the pre-allele model, recessive model, codominant model, or homozygotic model (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). No significant association was observed in the East Asian population (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

![Forest plot showing the association between RFC-1 80G\>A (rs1051266) polymorphism and MTX-related toxicity (dominant model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig6){#fig6-2040622320916026}

For the ABCB1 3435C\>T (rs1045642) polymorphism, seven studies (459 presenting adverse events and 586 without adverse events) were included in the meta-analysis. The ABCB1 3435C\>T (rs1045642) polymorphism was not related to the presence and/or absence of adverse events in the overall population (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). Moreover, significant between-study heterogeneity was observed in the dominant (I^2^ = 66.5, χ^2^ = 17.91, *p* = 0.006), recessive (I^2^ = 67.8, χ^2^ = 18.62, *p* = 0.005), and codominant models (I^2^ = 81, χ^2^ = 26.35, *p* \< 0.001) but not in other two models (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

By contrast, in the European population (92 presenting adverse events and 296 without adverse events), the ABCB1 3435C\>T (rs1045642) polymorphism was correlated with the absence of adverse events in the pre-allele model (OR = 0.622, 95% CI: 0.442--0.875, *p* = 0.006) ([Figure 7](#fig7-2040622320916026){ref-type="fig"}) and homozygotic model (OR = 0.389, 95% CI: 0.178--0.851, *p* = 0.018) ([Figure 8](#fig8-2040622320916026){ref-type="fig"}) but not in the dominant model, recessive model, or codominant model (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)). No significant association was observed in the East Asian population (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

![Forest plot showing the association between ABCB1 3435C\>T (rs1045642) polymorphism and MTX-related toxicity (pre-allele model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig7){#fig7-2040622320916026}

![Forest plot showing the association between ABCB1 3435C\>T (rs1045642) polymorphism and MTX-related toxicity (homozygotic model).\
CI, confidence interval; MTX, methotrexate; OR, odds ratio.](10.1177_2040622320916026-fig8){#fig8-2040622320916026}

The MTHFR 1298A\>C (rs1801131), MTR2756 A\>G (rs1805087), MTRR 66A\>G (rs1801394), FPGS 1994A\>G (rs10106), AMPD1 34C\>T (rs17602729), ITPA 94C\>A (rs1127354), GGH -401C\>T (rs3758149), GGH 16T\>C (rs1800909), GGH 452C\>T (rs11545078), ABCC2 C\>T (rs4148396), ABCG2 914C\>A (rs2231142),FPGS 2572C\>T(rs1544105), TYMS 28-bp tandem repeat (rs34743033), ADORA2A 4221164C\>T (rs2267076), ADORA2A 24429543C\>T (rs2298383), and MTHFD1 1958G\>A (rs2236225) polymorphisms were not correlated with the presence and/or absence of adverse events in the overall population, the European population or the East Asian population under five genetic models. (Additional file 2: [Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)).

Characteristics of the study population in the retrospective cohort study {#section14-2040622320916026}
-------------------------------------------------------------------------

The present study included 162 patients with RA, of which 83.95% were females, treated with MTX. No heterogeneity was detected for any other SNPs in our study. [Table 1](#table1-2040622320916026){ref-type="table"} summarizes the detailed demographic characteristics of the RA patients.

###### 

Characteristics of the patients in the retrospective cohort study.

![](10.1177_2040622320916026-table1)

                             RA patients, *N* = 162   Patients with AEs, *N* = 39
  -------------------------- ------------------------ -----------------------------
  Age (years)                52.99 ± 13.81            55 (48--64)
  Female (%)                 136 (83.95)              36/3
  BMI (kg/m^2^)              23.09 (20.70--25.53)     22.86 (21.05--22.45)
  Disease duration (years)   4 (2--10)                7 (2.00--13.00)
  Dose of MTX (mg/week)      10 (7.5--10)             10.00 (7.50--10.00)
  CRP (mg/dl)                1.49 (0.64--3.99)        1.28 (0.80--2.36)
  ESR (mm/hour)              30 (16.75--59.50)        25 (18.00--66.00)
  RF positive (%)            142 (95.95%)             100%
  CCP positive (%)           111 (82.84%)             87.88%
  AKA positive (%)           62 (54.87%)              58.62%
  ANA positive (%)           73 (58.87%)              66.67%
  DAS28-ESR                  5.17 ± 1.50              4.97 (4.01--6.25)

AE, adverse event; AKA, antikeratin antibody; ANA, antinuclear antibody; BMI, body mass index; CRP, C-reactive protein; CCP, cyclic peptide containing citrulline; DAS, disease activity score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor.

MTX-induced adverse events were observed in 39 patients (24.07%) during the course of treatment. Gastrointestinal side effects were the most frequent events (27/39 patients, 69.23%) including nausea, diarrhea, stomach pain, abdominal pain, indigestion, and anorexia, followed by elevations in liver transaminases (12/39 patients, 30.78%). Tiredness (6/39 patients, 15.38%), pain (1/39 patients, 2.56%), alopecia (1/39 patients, 2.56%), erythema of the extremities (1/39 patients, 2.56%), and lung disease (1/39 patients, 2.56%) also occurred.

Associations between gene polymorphisms and MTX adverse events {#section15-2040622320916026}
--------------------------------------------------------------

[Table 2](#table2-2040622320916026){ref-type="table"} presents a comparison of the distributions of the MTHFR 677C\>T (rs1801133), RFC-1 80G\>A (rs1051266), ATIC 347C\>G (rs2372536) and ABCB1 3435C\>T (rs1045642) polymorphisms between the groups of RA patients with and without adverse events. The genotype frequencies of the RA patients conformed to HWE (*p* \> 0.05). There was a significant difference in the RFC-1 80G\>A (rs1051266) polymorphism distribution between patients with and without adverse events (*p* = 0.02); however, there were no significant differences in the frequency distribution of genotypes and alleles for the MTHFR 677C\>T (rs1801133), ATIC 347C\>G (rs2372536), and ABCB1 3435C\>T (rs1045642) polymorphisms. We were unable to obtain results for MTHFR 677C\>T (rs1801133) polymorphism genotyping in one case and ABCB1 3435C\>T (rs1045642) polymorphism genotyping in five cases because the 260/280 ratios of these samples were not between 1.8 and 1.9. Finally, the total number of patients analyzed was 161 for the MTHFR 677C\>T (rs1801133) polymorphism and 157 for the ABCB1 3435C\>T (rs1045642) polymorphism.^[@bibr24-2040622320916026],[@bibr25-2040622320916026]^

###### 

Frequencies of genotypes in RA patients with and without MTX-induced adverse events.

![](10.1177_2040622320916026-table2)

  Genotypes or alleles                With AE (*n* = 39)   Without AE (*n* = 123)   *p* value   OR      95%CI
  ----------------------------------- -------------------- ------------------------ ----------- ------- ----------------
  MTHFR 677C\>T rs1801133 genotype                                                                      
  CC                                  7 (20.0)             22 (18.03)                                   
  CT                                  17 (42.5)            73 (59.84)               0.566       0.741   (0.266,2.064)
  TT                                  15 (37.5)            27 (22.13)               0.284       1.814   (0.610,5.393)
  Allele                                                                                                
  C                                   31 (41.25)           117 (47.95)                                  
  T                                   47 (58.75)           127 (52.05)              0.205               
  RFC-1 80G\>A rs1051266 genotype                                                                       
  GG                                  16 (42.5)            29 (23.58)                                   
  GA                                  20 (50.0)            69 (56.09)               0.144       2.923   (0.774,11.041)
  AA                                  3 (7.5)              25 (20.33)               0.009       6.523   (1.596,26.655)
  Allele                                                                                                
  G                                   52 (67.5)            127 (51.63)                                  
  A                                   26 (32.5)            119 (48.37)              0.020               
  ATIC 347C\>G rs2372536 genotype                                                                       
  CC                                  26 (67.5)            71 (62.83)                                   
  CG                                  12 (30.0)            45 (30.97)               0.423       0.725   (0.330,1.594)
  GG                                  1 (2.5)              7 (6.2)                  0.338       0.342   (0.038,3.077)
  Allele                                                                                                
  C                                   64 (82.5)            187 (78.32)                                  
  G                                   14 (17.5)            59 (21.68)               0.476               
  ABCB1 3435C\>T rs1045642 genotype                                                                     
  CC                                  16 (43.24)           38 (31.67)                                   
  CT                                  14 (37.84)           54 (45.0)                0.273       0.625   (0.270,1.448)
  TT                                  7 (18.92)            28 (23.33)               0.270       0.561   (0.201,1.568)
  Allele                                                                                                
  C                                   46 (62.16)           130 (54.17)                                  
  T                                   28 (37.84)           110 (45.83)              0.226               

ABC, adenosine triphosphate-binding cassette; AE, adverse event; ATIC, aminoimidazole-4-carboxamide ribonucleotide transformylase; CI, confidence interval; MTHFR, methylenetetrahydrofolate reductase; MTX, methotrexate; OR, odds ratio; RA, rheumatoid arthritis; RFC-1, reduced folate carrier 1.

Discussion {#section16-2040622320916026}
==========

MTX is a structural analog of folic acid that has anti-inflammatory and antiproliferative effects. However, its exact mode of action, predictors of treatment response, and adverse events in RA are not fully understood. Many studies have attempted to identify associations between MTX-related adverse events in RA and modifications of genes involved in the MTX mechanism of action, such as RFC-1, also known as the solute carrier family 19 folate transporter member 1 (SLC19A1); ABC, also called multidrug resistance protein 1 (MDR1), which is involved in the MTX membrane transport pathway; MTHFR, which is the most-studied genetic variant; dihydrofolate reductase (DHFR), FPGS, GGH, TYMS, ATIC, and ADORA2A, which are involved in MTX intracellular pathways.

Two SNPs in the MTHFR gene, rs1801133 and rs1801131, are the best known polymorphisms and are associated with a decline in enzyme activity that might be the potential cause of MTX-related toxicity in RA patients.^[@bibr63-2040622320916026]^ Previous meta-analyses conducted to verify the associations between MTHFR gene polymorphisms and MTX-related adverse events in RA patients have yielded inconsistent results. Fisher *et al*. performed a meta-analysis that showed that the 677C\>T polymorphism was associated with increased toxicity (OR 1.71, 95% CI 1.32--2.21, *p* \< 0.001), whereas the 1298A\>C polymorphism was not (OR 1.12, 95% CI 0.79--1.6, *p* = 0.626).^[@bibr10-2040622320916026]^ However, a meta-analysis performed by Lee *et al*. showed that neither the 677C\>T nor the 1298A\>C polymorphism of MTHFR was associated with MTX toxicity in RA, both in all patients and in Asian patients.^[@bibr11-2040622320916026]^ A meta-analysis performed by Song and colleagues showed that the MTHFR 677C\>T (rs1801133) polymorphism was associated with MTX-induced toxicity in RA patients in the East Asian population,^[@bibr15-2040622320916026]^ which is consistent with our findings.

ATIC is involved in the *de novo* synthesis of purine and converts aminoimidazole carboxamide adenosine ribonucleotide (AICAR) to formyl-AICAR,^[@bibr64-2040622320916026]^ which inhibits adenosine and AMP deaminase, resulting in increased adenosine and AMP concentrations.^[@bibr65-2040622320916026]^ MTX is transformed to MTX polyglutamates (MTX-PGs) after entering cells and directly inhibits ATIC,^[@bibr66-2040622320916026]^ leading to intracellular accumulation of AICAR and extracellular release of adenosine, which produces anti-inflammatory effects.^[@bibr67-2040622320916026]^ A meta-analysis by Lee *et al*.^[@bibr19-2040622320916026]^ indicated a significant association between the ATIC 347 GG + GC genotype and MTX toxicity in Caucasian (OR = 1.741, 95% CI 1.080--2.806, *p* = 0.023) but not in Asian patients, which is consistent with our findings. However, Chen *et al*.^[@bibr68-2040622320916026]^ found that ATIC 347 C\>G was not associated with MTX toxicity in Caucasians.

After entering the body, MTX enters cells *via* the action of RFC, a member of the solute carrier (SLC) family of uptake-type transporters. MTX is transported outside cells by the actions of ABCC1, ABCC2, ABCC3, ABCC4, and ABCB1, which are members of the ABC family of discharge-type transporters.^[@bibr54-2040622320916026]^ The SLC19A1/RFC-1 80G\>A (rs1051266) polymorphism is one of the most well-studied polymorphisms of the SLC/RFC gene. A total of 12 studies included in our meta-analysis investigated the association between MTX treatment toxicity and the SLC19A1/RFC-1 80G\>A (rs1051266) polymorphism. The results showed that the SLC19A1/RFC-1 80G\>A (rs1051266) polymorphism was associated with MTX treatment toxicity in the European population under the dominant model (OR = 1.352, 95% CI: 1.039--1.760, *p* = 0.025) but not in the East Asian population. However, this finding is not consistent with two previous meta-analyses that found that the SLC19A1/RFC-1 80G\>A (rs1051266) polymorphism was not related to MTX treatment toxicity.^[@bibr16-2040622320916026],[@bibr18-2040622320916026]^ Differences in the inclusion and exclusion criteria are the main reasons for these inconsistent findings. The ABCB1/MDR1 3435C\>T (rs1045642) polymorphism is one of the most-studied polymorphisms of the ABCB1 gene, and seven studies included in our meta-analysis investigated the association between MTX-related toxicity and the ABCB1/MDR1 3435C\>T (rs1045642) polymorphism. The results showed that ABCB1 3435C\>T (rs1045642) was associated with MTX treatment toxicity in the European population under the pre-allele (OR = 0.622, 95% CI: 0.442--0.875, *p* = 0.006) and homozygotic (OR = 0.389, 95% CI: 0.178--0.851, *p* = 0.018) model but not in the East Asian population. Moreover, in 2016, a meta-analysis conducted by Lee *et al*. indicated that MTX toxicity was associated with the ABCB1 3435C\>T (rs1045642) polymorphism in RA (TC *versus* TT + CC; OR 0.483, 95% CI 0.259--0.900, *p* = 0.022).^[@bibr17-2040622320916026]^ Taken together, these findings suggested that the ABCB1 3435C\>T (rs1045642) polymorphism might be associated with MTX toxicity in RA.

In this updated meta-analysis, five genetic models were performed to test the association of the polymorphisms and adverse events of MTX, which showed superiority compared with our previous meta-analysis,^[@bibr22-2040622320916026]^ which using a specific dominant model. Various genetic models ensured some interesting findings were not missed and the results more rigorously demonstrated absence and presence of association. Moreover, different from our previous meta-analysis, in which 31 studies were included in seven meta-analyses, there were 39 articles included in 20 meta-analyses in this updated-analysis. As for the results, different from our previous study, significant associations were observed between the MTHFR (677C \> T (rs1801133) and MTX toxicity in East Asian RA patients, and ATIC 347C \> G (rs2372536) and ABCB1 3435C \> T (rs1045642) in European RA patients in this updated meta-analysis, and FPGS 1994A\>G (rs10106), AMPD1 34C\>T (rs17602729), ITPA 94C\>A (rs1127354), GGH -401C\>T (rs3758149), GGH 16T\>C (rs1800909), GGH 452C\>T (rs11545078), ABCC2 C\>T (rs4148396), ABCG2 914C\>A (rs2231142),FPGS 2572C\>T(rs1544105), TYMS 28-bp tandem repeat (rs34743033), ADORA2A 4221164C\>T (rs2267076), ADORA2A 24429543C\>T (rs2298383) and MTHFD1 1958G\>A (rs2236225) polymorphisms were not associated with the presence and/or absence of adverse events in the overall population, the European population, or the East Asian population.

As mentioned above, when stratification analysis was conducted by ethnicity, we observed that the ABCB1 3435C\>T (rs1045642)polymorphism and ATIC 347C\>G (rs2372536) polymorphism were not associated with MTX-related toxicity in the East Asian population of RA patients, and the results of our retrospective cohort study were consistent with these findings. However, the results of our retrospective cohort study showed that the MTHFR 677C\>T (rs1801133) polymorphism was not associated with MTX-induced toxicity, but RFC-1 80G\>A (rs1051266) polymorphism was associated with MTX-induced toxicity, which was not consistent with the evidence-based findings derived from our meta-analysis.

Although we conducted a meta-analysis and obtained convincing evidence-based results that were also validated by a retrospective study, certain limitations of our study should be noted. First, only studies published in English were included, which may result in potential study selection bias. Second, publication bias could have distorted our meta-analysis because of the small number of included studies. We included 23, 20, 7, 5, 4, 12, 7, 4, 4, and 3 studies in the meta-analyses of the MTHFR 677C\>T (rs1801133), MTHFR 1298A\>C (rs1801131), ATIC 347C\>G (rs2372536), MTR 2756A\>G (rs1805087), MTRR 66A\>G (rs1801394), RFC-1 80G\>A (rs1051266), ABCB1 3435C\>T (rs1045642), FPGS 1994A\>G (rs10106), AMPD1 34C\>T (rs17602729), and ITPA 94C\>A (rs1127354) polymorphisms, respectively, and 2 studies in the meta-analyses of the GGH -401C\>T (rs3758149), GGH 16T\>C (rs1800909), GGH 452C\>T (rs11545078), ABCC2 C\>T (rs4148396), ABCG2 914C\>A (rs2231142), FPGS 2572C\>T (rs1544105), TYMS 28-bp tandem repeat (rs34743033), ADORA2A 4221164C\>T (rs2267076), ADORA2A 24429543C\>T (rs2298383), and MTHFD1 1958G\>A (rs2236225) polymorphisms. Third, heterogeneity and confounding factors may have affected the meta-analysis. Variables such as study design, sex, rheumatoid factor status, disease duration, dose of MTX, folic acid supplementation, limited number of tested SNPs, and even patient's medical files all have the potential influence to this analysis. Fourth, for the retrospective cohort study, we performed a genetic analysis only of the MTHFR 677C\>T (rs1801133), ATIC 347C\>G (rs2372536), RFC-1 80G\>A (rs1051266), and ABCB1 3435C\>T (rs1045642) polymorphisms in a Chinese Han population, and the sample size was also limited.

The major issue surrounding low-dose MTX pharmacogenetics is the failure of reported associations to survive replication in one or more independent cohorts. Nonreplication across studies is attributed largely to insufficient statistical power and an array of pharmacological and clinical confounders.^[@bibr69-2040622320916026]^ In this up-dated meta-analysis, a total of 39 pharmacogenetic studies on low-dose MTX were included, and most of them (23/39) had less than 200 RA patients (Additional file 1: [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2040622320916026)), and therefore have limited power to detect the effect sizes routinely reported. Statistical power is then further reduced by the requirement to adjust for multiple testing,^[@bibr26-2040622320916026]^ but, besides that, variability in the outcome definitions and the heterogeneity of the cohorts, limited number of tested SNPs, small effect for the selected variant, and a lack of consideration of epigenetic factors, may contribute to the inconsistency observed. The use of more powerful technologies, including proteomics and transcriptomic studies, genome-wide association studies (GWAS), together with epigenetic factors, large samples and high-quality associated clinical data, will be essential to detect more genetic factors responsible for variability in MTX responses.^[@bibr70-2040622320916026]^

Conclusion {#section17-2040622320916026}
==========

In summary, our updated meta-analysis showed that one SNP in the MTHFR gene, rs1801133, was significantly associated with MTX-related adverse events in the East Asian population, while one SNP in the ATIC gene, rs2372536; one SNP in the RFC-1 gene, rs1051266; and one SNP in the ABCB1 gene, rs1045642; were significantly associated with MTX-related adverse events in the European population. However, the retrospective cohort study indicated that MTHFR 677C\>T (rs1801133) polymorphism was not associated with MTX-induced toxicity, but RFC-1 80G\>A (rs1051266) polymorphism was associated with MTX-induced toxicity in the Chinese Han population, which is inconsistent with the results of our meta-analysis. Although meta-analysis is a powerful tool for evaluating and summarizing knowledge in a research field through statistical instruments, it can also be limited by confounding factors. All of these findings may require well-designed studies with larger sample sizes for further validation.
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